Advances in AI helping healthcare providers, patients throughout Asia

AI technologies are making a significant impact on the health of patients throughout Asia, according to a new report from MIT Technology Review Insights.

The 25-page report, “AI in health care: Capacity, capability and the future of active health in Asia,” is available on the MIT Technology Review Insights website. Baidu, a technology company based out of Beijing, China, sponsored its development.

Much of Asia is currently suffering from strained resources, and the situation is expected to get much worse in the years ahead. Fortunately, the report’s authors explained, advances in AI have helped provide some sense of relief for both healthcare providers and patients themselves.

The report also emphasized that it’s not just advances in AI that are important—its being able to explain how AI works to the public. The actual technology must ultimately still take a “supporting role” as the physicians themselves take the lead and engage patients as needed.

“By 2030, the World Health Organization estimates that Asia will require 12 million more healthcare professionals,” Claire Beatty, the report’s editor, said in a prepared statement. “Without AI technologies for increasing capacity, systems simply will not cope. The combination of government goal-setting and private sector R&D is a really promising development for healthcare innovation.”

“AI developments make high-quality medical resources more accessible, increase resource-sharing, and improve the efficiency of diagnosis and treatments,” Haifeng Wang, chief technology officer of Baidu, said in the same statement.

The report contrasts another recent finding that the AI hype in China––where a significant amount of investment has been taking place in the AI space––may be exceeding the actual output. Only a handful of platform technologies and market segments are seeing new innovations with AI products, the research report found.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.